Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies-Reference-Cited by-同舟云学术

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies

Published:2014-11 Issue:11 Volume:21 Page:1835-1846
ISSN:0967-5868
Container-title:Journal of Clinical Neuroscience
language:en
Short-container-title:Journal of Clinical Neuroscience

Author:

Broadley Simon A.,Barnett Michael H.,Boggild Mike,Brew Bruce J.,Butzkueven Helmut,Heard Robert,Hodgkinson Suzanne,Kermode Allan G.,Lechner-Scott Jeannette,Macdonell Richard A.L.,Marriott Mark,Mason Deborah F.,Parratt John,Reddel Stephen W.,Shaw Cameron P.,Slee Mark,Spies Judith,Taylor Bruce V.,Carroll William M.,Kilpatrick Trevor J.,King John,McCombe Pamela A.,Pollard John D.,Willoughby Ernest

Publisher

Elsevier BV

Subject

Physiology (medical),Clinical Neurology,Neurology,General Medicine,Surgery

Reference231 articles.

1. Multiple sclerosis;Compston;Lancet,2008

2. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000;Mayr;Neurology,2003

3. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity;Roxburgh;Neurology,2005

4. Measurement of health-related quality of life in multiple sclerosis patients;Brunet;Can J Neurol Sci,1996

5. Access Economics Pty Ltd., Acting positively: strategic implications of the economic costs of MS in Australia: Multiple Sclerosis Research Australia; 2005.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-modifying therapies do not affect sleep quality or daytime sleepiness in a large Australian MS cohort;Multiple Sclerosis and Related Disorders;2023-10

2. Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis;Journal of Neurology, Neurosurgery & Psychiatry;2022-07-28

3. Impact of remoteness on patient outcomes for people with multiple sclerosis in Australia;Multiple Sclerosis and Related Disorders;2021-10

4. Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis;Multiple Sclerosis Journal;2020-09-03

5. Differential multiple sclerosis treatment allocation between Australia and New Zealand associated with clinical outcomes but not mood or quality of life;Multiple Sclerosis and Related Disorders;2019-05